Scarica l'app Stockscreener
1.725
0.29%
-0.015
Dopo l'orario di chiusura:
1.73
0.005
+0.29%
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year - TipRanks
Taysha Gene Therapies Inc Reports Full Year 2024 EPS of -$0.36 a - GuruFocus.com
Earnings call transcript: Taysha Gene's Q4 2024 reports narrower loss, stock dips - Investing.com
Earnings call transcript: Taysha Gene’s Q4 2024 reports narrower loss, stock dips - Investing.com India
Taysha Gene Therapies, Inc. SEC 10-K Report - TradingView
Can Taysha's Gene Therapy for Rett Syndrome Deliver? Key Safety Milestone Reached as Cash Extends to 2026 - StockTitan
Taysha Gene Therapies: Promising Advancements and Financial Stability Drive Buy Rating - TipRanks
Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World
Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times
Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Taysha Gene Therapies Inc [TSHA] Records 50-Day SMA of $1.9835 - Knox Daily
Taysha's Strategic Move: 491K Stock Options Awarded to Secure Top Industry Talent - StockTitan
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Prepare Yourself for Liftoff: Taysha Gene Therapies Inc (TSHA) - SETE News
Octagon Capital Advisors LP Increases Stake in Taysha Gene Thera - GuruFocus.com
Scienjoy Holding Leads Our 3 US Penny Stocks To Consider - Simply Wall St
Taysha Gene Therapies Inc (TSHA)’s Market Momentum: Closing Strong at 1.53, Up 2.00 - The Dwinnex
Technical analysis of Taysha Gene Therapies Inc (TSHA) stock chart patterns - US Post News
Taysha Gene Therapies Is Showing Promise For Rett Syndrome - Seeking Alpha
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More - MedCity News
Cantor Fitzgerald Predicts TSHA FY2025 Earnings - Defense World
Brokers Issue Forecasts for TSHA FY2025 Earnings - MarketBeat
Illuminating Rett syndrome: Latest pharmacological advancements - The Pharma Letter
Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) PT at $6.63 - MarketBeat
Barclays PLC Increases Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Barclays PLC Boosts Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Jane Street Group LLC Sells 20,552 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
5.68%
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):